Vitamin D and Mortality in Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01326650
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
- Registry
-
NCT01326650
-
- Other papers using this trial's data
- Daily Supplementation with 4000 IU Vitamin D3 for Three Years Does Not Modify Cardiovascular Risk Markers in Patients with Advanced Heart Failure: The Effect of Vitamin D on Mortality in Heart Failure Trial
- Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily
- Randomized supplementation of 4000 IU vitamin D3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01326650. Randomized; quadruple masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2016-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vitamin D and Mortality in Heart Failure
- Acronym
- EVITA
- Condition
- Congestive Heart Failure
- Intervention (Drug)
- Vitamin D
- Intervention (Drug)
- placebo
- Lead sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Record details
- Record id
cardio:ct-nct01326650- Content hash
d25367b49441a7e397f16ba97665af0d0db3da1c853a06b75ab1f22cd67268c0